Cellular immunogenicity of human papillomavirus vaccines Cervarix and Gardasil in adults with HIV infection.

about

Cellular immunogenicity of human papillomavirus vaccines Cervarix and Gardasil in adults with HIV infection.

Item

http://www.wikidata.org/entity/Q49664919

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Cellular immunogenicity of hum ...... in adults with HIV infection.

@en

Cellular immunogenicity of hum ...... in adults with HIV infection.

@nl

type

Item

label

Cellular immunogenicity of hum ...... in adults with HIV infection.

@en

Cellular immunogenicity of hum ...... in adults with HIV infection.

@nl

prefLabel

Cellular immunogenicity of hum ...... in adults with HIV infection.

@en

Cellular immunogenicity of hum ...... in adults with HIV infection.

@nl

P1476

Cellular immunogenicity of hum ...... in adults with HIV infection.

@en

P2093

Andreas M Kaufmann

http://www.w3.org/2001/XMLSchema#string

Lars Toft

http://www.w3.org/2001/XMLSchema#string

Maria Zurek Munk-Madsen

http://www.w3.org/2001/XMLSchema#string

Rolf Richter

http://www.w3.org/2001/XMLSchema#string

Tina Kube

http://www.w3.org/2001/XMLSchema#string

P2860

Microbial translocation is a cause of systemic immune activation in chronic HIV infection

Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years

Priming of human papillomavirus type 11-specific humoral and cellular immune responses in college-aged women with a virus-like particle vaccine

Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old.

Spectrum of AIDS-associated malignant disorders.

Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men

Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: follow-up through Month 48 in a Phase III randomized study.

Prevalence and risk factors for HPV in HIV-positive young women receiving their first HPV vaccination.

Humoral, mucosal, and cell-mediated immunity against vaccine and nonvaccine genotypes after administration of quadrivalent human papillomavirus vaccine to HIV-infected children

Comparison of the immunogenicity of Cervarix® and Gardasil® human papillomavirus vaccines for oncogenic non-vaccine serotypes HPV-31, HPV-33, and HPV-45 in HIV-infected adults.

P304

909-916

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/21645515.2017.1407896

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Martin Tolstrup

Lars Østergaard

Ole Schmeltz Søgaard

P577

2017-12-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29172992

http://www.w3.org/2001/XMLSchema#string

P932

5893199

http://www.w3.org/2001/XMLSchema#string